Cell therapy for central nervous system disorders: Current obstacles to progress. (17th October 2019)

• Record Type: Journal Article
• Authors: Yasuhara, Takao; Kawauchi, Satoshi; Kin, Kyohei; Morimoto, Jun; Kameda, Masahiro; Sasaki, Tatsuya; Bonsack, Brooke; Kingsbury, Chase; Tajiri, Naoki; Borlongan, Cesario V.; Date, Isao
• Other Names: Bailes Julian E. guestEditor.; Borlongan Cesar V. guestEditor.
• Is Part Of: CNS neuroscience & therapeutics. Volume 26:Number 6(2020)
• Page Start: 595
• Page End: 602
• Publication Date: 2019-10-17
• Subjects: cell therapy -- iPS cells -- Parkinson's disease -- stroke -- traumatic brain injury; Neuropharmacology -- Periodicals; Central nervous system -- Diseases -- Effect of drugs on -- Periodicals; 612.8
• DOI: 10.1111/cns.13247
• Languages: English
• ISSNs: 1755-5930

Abstract

Abstract: Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue‐derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor‐secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.